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Picking Some News about the Retroviral Vector World
from the 9th Symposium of the European Society
of Gene Therapy
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The 9th symposium of the European Society of Gene Therapy (ESGT) organized by Murat Tuncer (President of the Meeting),
Bernd Gansbacher (President of the ESGT), and Meral Ozguc (Secretary of the Meeting) took place in Antalya, South Turkey, on
2–4 November 2001. Although the international political context made diﬃcult the coming of some researchers, this symposium
has drawn an interesting picture of the works in progress in Europe and in the Mediterranean area.
The emergence of lentiviral vectors, mainly derived from
human immunodeﬁciency virus (HIV) type 1, at the end of
theninetieslargelyopenedthepossibilitytomanipulatecells,
which was not considered as classical target cells of the retro-
viral gene transfer strategy, or which failed to be success-
fully genetically manipulated using murine leukemia virus
(MLV) derived vectors [1]. Taking advantage of the exper-
tise in retroviral vector design raised from the past twenty
years, lentiviral backbones have rapidly exhibited common
featureswiththelatestMLVderivedbackbones,allowingnu-
m e r o u sw o r k st ob ec a r r i e do u tt oc o m p a r eM L Vd e r i v e d
vectors with lentiviral vectors. Since 1996 with the Naldini’s
paper describing the possibility to construct and produce
HIV-1 derived vectors [2], during the previous ESGT meet-
ings only few oral or poster presentations have reported the
use of lentivirus derived vectors as compared to adenoviral
vectors or adeno-associated virus (AAV) derived vectors. In
2001, numerous reports highlighted the use of lentiviral vec-
tors and pointed out the interest of these vectors.
TRANSDUCTION EFFICIENCY: STILL THE GOLDEN
GOAL, BUT ...
The testing of new transduction procedures, the interest
of additional cis-active sequences such as the central DNA
ﬂap sequence in lentiviral vector that improves the trans-
duction of several cell types, the design of new production
processes that enable the use of high doses of vectors in
vivo, ... increasing the transduction eﬃciency to reach the
100% golden goal is a classical duty for people working on
gene therapy. But most of the works presented focused on
the ﬁnding of equilibrium between transduction eﬃciency
and quality of the expression. The combination of the in-
hibition of the expression of the HIV long terminal repeat
in tat-deﬁcient cells and the possibility to use eﬃcient self
inactivating backbones that exhibit deletion of the viral pro-
moter in the transduced cell, allowed numerous works to fo-
cus on eﬃcient expression strategies. The strength and the
expression kinetics of the so-called constitutive promoters
can vary from a cell type to another, which makes diﬃ-
cult to ascertain the interest of only one promoter. In spite
of this diﬃculty, the phosphoglycerate kinase (PGK) and
the elongation factor 1-alpha (EF1-alpha) gene promoters
have been shown to eﬃciently and for long-term express
lentivirally transduced marker genes in various cell types,
such as hepatocarcinoma cells, hematopoietic cells, or cen-
tral nervous system cells, among several constitutive pro-
moters tested including the cytomegalovirus derived pro-
moter, the human alpha antitrypsin gene promoters, and
the chimeric CAG promoter. Beside constitutive expression,
strong eﬀorts are developed to control the expression of the
transgene using tissue-speciﬁc promoters in lentiviral vec-
tors. The use of the promoter of the CD4 gene to induce the
transcription of the transgene expression unit in CD4 lym-
phocytes, the insulin gene promoter in hepatocytes, modi-
ﬁed versions of the ankyrin gene promoter or the locus con-
trol region of the beta-globin gene in erythropoietic cells,
an epidermal growth factor responsive promoter in epithe-
lial cells, ... very interesting works have demonstrated the
possibility to achieve a selective strong expression in target
cells with low level basal expression in non selected cells.
Although promising, whether these in vitro models will be
successfully transposed to the in vivo approaches remains to
be shown. Multiple gene expressing vectors are being tested
but—although one work showed an elegant penta-cistronic
MLV based vectors, those eﬃcacy and interest remain to be
proven—MLV and lentiviral vectors are still dealing with the
expression of two genes at maximum with classical coexpres-
sion strategies relying on internal ribosomal entry site ele-
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of cleavable bi-functional precursor proteins, or multiple
promoters.
THE IN VIVO TRAP
Both as a way to control the expression and as a safety
feature for in vivo approaches, targeting the binding of the
viral particle is still highly considered but with the works
only conducted by a few expert groups. The strategies ap-
proached with MLV derived vectors to redirect the surface
protein (SU) are now being tested with lentiviral particles
in vitro with moderate success in terms of transduction eﬃ-
ciency. For example, the targeting of T lymphocytes has been
engineered by the use of MLV vectors pseudotyped by SU
molecules from HIV, or pseudotyped by the coexpression of
the VSV-G envelope protein with a T cell activating peptide
from the anti-CD3 OKT3 monoclonal antibody at the viral
particle surface. The natural trapping of viral particles by the
liver, the spleen, and to a lower extent by the lung, makes
diﬃcult the possibility of achieving eﬃcient transduction by
systemicinjectionoftheviralparticlesandmarkedlyempha-
sizestheinterestofthetargetingstrategy.Butitistonotethat
the potential trapping of targeted particles by these ﬁlter or-
gans remains to be addressed.
The immune reaction makes another in vivo trap for
both viral particles and transduced cells. The pseudotyp-
ing of lentiviral particles with new surface proteins such as
derivatives of the RD114 virus SU, and the use of highly pu-
riﬁed vector batches in vivo to prevent from cell mediated
immune reaction, demonstrate that the immunological as-
pects of the lentiviral particle have also to be carefully con-
sidered. However, as it has been shown several years ago with
MLV vectors, it seems that the moderate immune reaction
observed after injection is not suﬃcient to abolish primary
or reiterated gene transfer.
BEYOND THE MARKER GENES
Most of the strategies using MLV vectors are now being
approached by lentiviral vectors with the treatment of hema-
tological genetic diseases such as the Zap-70 deﬁciency re-
lated severe combined immunodeﬁciency (SCID), the pro-
toporphyria,thechronicgranulomatousdisease,orthetreat-
ment of pathologies that could beneﬁt from the ectopic ex-
pression of the transgene such as the ectopic expression
of coagulation factors in liver cells for the treatment of
hemophilia. For anti-cancer purposes, the genetic manipu-
lation of cells involved in the immune reaction such as den-
dritic cells is a classical strategy relying on the possibility
to express tumor associated antigens, such as Melan A, ty-
rosinase, gp100, or MAGE-3 to elicit melanoma speciﬁc im-
mune responses. Most, if not all, the viral vectors have been
tested to transduce dendritic cells and lentiviral vectors can
be considered as interesting tools to genetically manipulate
these types of cells. It is to note that several reports favor
the use of DNA-ﬂap sequence containing lentiviral vectors
to genetically manipulate dendritic cells deriving either from
hematopoietic progenitors or monocytes. Considering that
the interest of the lentiviral vector for the transduction of T
lymphocyte remains to be ﬁrmly proven, most of the works
relying on genetic manipulation of T cells, such as transfer
of the herpes simplex virus derived thymidine kinase gene
to manipulate graft-versus-host disease, or the expression of
interleukin-10 to modulate the immune response, did not
switch to the lentiviral vector technology, yet.
Lentiviral vectors can be of strong interest to transduce
nondividing cells in the treatment of some pathologies usu-
ally approached by adenoviral vectors or AAV derived vec-
tors. For example, lentiviral gene transfer into neuronal cells
in vivo has been reported for the study or the treatment of
diseases aﬀecting the central nervous system, with the trans-
fer of the Huntington protein to produce a model of Hunt-
ington disease, or the lentiviral transfer of the GDNF for the
treatment of Parkinson’s disease.
FROM THE BENCH TO THE BEDSIDE: WAITING FOR
SOME INDUSTRIAL IMPROVEMENTS TO MAKE THE
CHOICE BETWEEN MLV AND LENTIVIRAL VECTORS
The main limitations of the lentiviral vector strategy re-
main the large-scale production and clinical development.
These two issues, which still have to be addressed, keep at-
tracting some strategies using MLV derived vectors for some
applications.
The design of large-scale production of lentiviral vectors
is in process. However, information about this technologi-
cal development is diﬃcult to obtain from people or compa-
nies involved in such projects, mainly due to conﬁdentiality
agreement barriers. Safety concerns regarding lentiviral vec-
tors have not been ﬁrmly discussed but was present as an ul-
terior motive in the presentations dealing with this strategy.
It is unfortunate to notice that discussions on the develop-
ment of replication competent virus (RCV) assay to detect
fullyreplicationcompetentcontaminantsorintermediatere-
combinant genomes that could favor RCV occurrence, were
absent from the presented works.
Beyond the technological problems, some cell types such
as proliferating T lymphocytes can be eﬃciently transduced
and selected using either lentiviral or MLV vectors. In addi-
tion, the gene therapy treatment of some pathologies, such
as the gamma c chain deﬁciency SCID, a priori, does not re-
quire the use of lentiviral vectors. In some instances, such
considerationsfavortheuseofMLVvectorsthatisanalready
clinically available concept.
FROM MLV VECTORS TO LENTIVIRAL VECTORS:
AN IN-BETWEEN PERIOD?
The evolution of MLV vector seems to pass by a plateau.
Conversely, according to the large area of possibilities still
opened for the design and the in vitro and in vivo use of
lentiviral vectors, strong evolutions of the lentiviral vector
strategy have to be envisioned in the near future. Lentiviral
vectors can be considered now as very interesting tools to
focus on. But MLV derived vectors are not becoming old-
fashioned tools. The information feedback we can expect6 Claude Bagnis 2:1 (2002)
from any progress in this ﬁeld will help us to improve pre-
viously approached gene transfer vectors or will allow us to
reconsider the way to use them. Beyond their intrinsic prop-
erties, lentiviral vectors will also help us to make a step fur-
ther in gene transfer technology using MLV vectors or other
tools.
To allow this overall improvement in gene therapy,
whether the use of lentiviral vectors can impact the thera-
peutical achievement expected in gene therapy has now to be
demonstrated. A ﬁrst clinical trial using lentiviral vectors has
been discussed at the Recombinant DNA Advisory Commit-
tee (RAC) session on 2001 [3]. The way is opened.
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